In life sciences, where innovation and unpredictability go hand in hand, a straight-line career path is the exception rather ...

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite ...

EY's Arda Ural provides an assessment of the current life sciences business environment, and reasons for optimism about 2025 despite the uncertainty that comes with a new administration in the U.S.

Memo Therapeutics CEO Erik van den Berg reflects on the strategies and skills needed to build company resilience and navigate ...

Novo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal ...

Life sciences legal departments can do more to improve financial efficiency across an organization. This article includes ...

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...